{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:13:53Z","timestamp":1792088033961,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.ygyno.2013.04.019","type":"journal-article","created":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T07:06:12Z","timestamp":1366268772000},"page":"75-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"title":["Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers"],"prefix":"10.1016","volume":"130","clinical-trial-number":[{"clinical-trial-number":"nct00941070","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Charles A.","family":"Kunos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Radivoyevitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Waggoner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Debernardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Resnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Redline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Faulhaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afshin","family":"Dowlati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2013.04.019_bb0005","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1200\/JCO.2006.09.4532","article-title":"Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Rose","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0010","doi-asserted-by":"crossref","first-page":"503.e1","DOI":"10.1016\/j.ajog.2007.08.003","article-title":"Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial","volume":"197","author":"Stehman","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1477-7800-3-3","article-title":"Prognostic significance of pathological response after neoadjuvant chemotherapy or chemoradiation for locally advanced cervical carcinoma","volume":"3","author":"Candelaria","year":"2006","journal-title":"Int Semin Surg Oncol"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0020","doi-asserted-by":"crossref","first-page":"351.e1","DOI":"10.1016\/j.ajog.2010.05.005","article-title":"Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma: a Gynecologic Oncology Group Study","volume":"203","author":"Kunos","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0025","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/IGC.0b013e31821dc8b5","article-title":"18F-fluoro-2-deoxy-d-glucose positron emission tomography standard uptake value as an indicator of cervical cancer chemoradiation therapeutic response","volume":"21","author":"Kunos","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0030","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.ijrobp.2007.04.015","article-title":"Primary vaginal cancer treated with concurrent chemoradiation using cis-platinum","volume":"69","author":"Samant","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0035","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.2967\/jnumed.108.057257","article-title":"The role of 18F-FDG PET in assessing therapy response in cancer of the cervix and ovaries","volume":"50","author":"Schwartz","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0040","first-page":"2245","article-title":"Expression of ribonucleotide reductase after ionizing radiation in human cervical carcinoma cells","volume":"58","author":"Kuo","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0045","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/35003506","article-title":"A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage","volume":"404","author":"Tanaka","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0050","doi-asserted-by":"crossref","first-page":"7834","DOI":"10.1074\/jbc.M512894200","article-title":"Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells","volume":"281","author":"Hakansson","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0055","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1158\/1078-0432.CCR-08-2257","article-title":"Changes in gene expression predicting local control in cervical cancer: results from Radiation Therapy Oncology Group 0128","volume":"15","author":"Weidhaas","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0060","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1667\/RR1858.1","article-title":"Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein","volume":"172","author":"Kunos","year":"2009","journal-title":"Radiat Res"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0065","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1667\/RR2273.1","article-title":"Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers","volume":"174","author":"Kunos","year":"2010","journal-title":"Radiat Res"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0070","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.ijrobp.2011.01.034","article-title":"Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: enhanced radiation response at low dose rates","volume":"80","author":"Kunos","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0075","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1667\/RR2556.1","article-title":"Deoxynucleoside salvage facilitates DNA repair during ribonucleotide reductase blockade in human cervical cancers","volume":"176","author":"Kunos","year":"2011","journal-title":"Radiat Res"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0080","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0360-3016(79)91209-4","article-title":"Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis","volume":"5","author":"Hreshchyshyn","year":"1979","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0085","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1200\/JCO.2004.07.197","article-title":"Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90-01","volume":"22","author":"Eifel","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0090","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1200\/JCO.1999.17.5.1339","article-title":"Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study","volume":"17","author":"Whitney","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0095","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1200\/JCO.2009.25.9663","article-title":"A phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix","volume":"29","author":"Duenas-Gonzalez","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0100","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-09-2469","article-title":"Phase I trial of intravenous 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in combination with pelvic radiation therapy and weekly cisplatin chemotherapy for locally advanced cervical cancer","volume":"16","author":"Kunos","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0105","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2217\/fon.11.147","article-title":"Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone induced methemoglobinemia","volume":"8","author":"Kunos","year":"2012","journal-title":"Future Oncol"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.17925\/OHR.2012.08.1.55","article-title":"Therapeutic mechanisms of treatment in cervical and vaginal cancer","volume":"8","author":"Kunos","year":"2012","journal-title":"Oncol Hematol Rev"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0115","first-page":"1059","article-title":"Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials","volume":"47","author":"Shankar","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0120","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumor response using 18F-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0125","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0130","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","article-title":"Accelerated titration designs for phase 1 clinical trials in oncology","volume":"89","author":"Simon","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0135","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0140","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0145","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJM199904153401502","article-title":"Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer","volume":"340","author":"Rose","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0150","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1667\/RR2273.1","article-title":"Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers","volume":"174","author":"Kunos","year":"2010","journal-title":"Radiat Res"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0155","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/cyto.b.20450","article-title":"Kinetics of H2AX phosphorylation after exposure to cisplatin","volume":"76B","author":"Olive","year":"2009","journal-title":"Cytometry Part B"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0160","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1479-5876-10-79","article-title":"Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group study","volume":"10","author":"Kunos","year":"2012","journal-title":"J Transl Med"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0165","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.radonc.2011.07.012","article-title":"Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer","volume":"100","author":"P\u00f6tter","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0170","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.ijrobp.2011.03.049","article-title":"Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results","volume":"82","author":"Dimopoulos","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0175","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1548-5315(11)70424-7","article-title":"Implementing chemoradiation treatment for patients with cervical cancer in a comprehensive cancer center community oncology practice","volume":"7","author":"Kunos","year":"2010","journal-title":"Commun Oncol"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2008\/931532","article-title":"Chemotherapy administration during pelvic radiation for cervical cancer patients aged \u226555years in the SEER-Medicare population","volume":"2008","author":"Kunos","year":"2008","journal-title":"J Oncol"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0185","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/IGC.0b013e3181b33ace","article-title":"Retrospective analysis of concomitant cisplatin during radiation in patients aged \u226555years for treatment of advanced cervical cancer: a Gynecologic Oncology Group Study","volume":"19","author":"Kunos","year":"2009","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2013.04.019_bb0190","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00280-011-1779-5","article-title":"A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced stage solid cancers\u2014a California Cancer Consortium Study","volume":"69","author":"Chao","year":"2012","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813002394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813002394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T15:52:39Z","timestamp":1562946759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813002394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0090825813002394"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.04.019","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718006599.793478004","asserted-by":"object"}]},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}